|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Bayer HealthCare's Consumer Care Division, a global marketer of over-the-counter medications and nutritional supplements. |
|---|---|
| Transferring Party | The Citracel® line of OTC calcium supplements of Mission Pharmacal Company, a family-owned pharmaceutical company based in Texas. |
| Sector | OTC/Consumer |
| Date | August 30, 2007 |
| Analysis Increases Bayer's OTC market presence in the U.S. and opens up international sales opportunities for extending the brand in other parts of the world. Bayer's other OTC products include Bayer(R) Aspirin, ALEVE(R), Flanax(R)/Apronax(R), Alka-Seltzer (R), Bactine(R), Phillips'(R) Milk of Magnesia, Midol(R), One-A-Day(R) vitamins, and Flintstones(TM) vitamin. Terms not disclosed; Citracel's sales are $54. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |